12 results on '"Corina Bara"'
Search Results
2. Unusual Skin Involvement in Statin-induced Anti-HMGCR Immune-mediated Necrotizing Myopathy
- Author
-
Camille Scard, Corina Bara-Passot, Kévin Chassain, and Hervé Maillard
- Subjects
myositis/immunology ,skinpathology ,myopathy ,Dermatology ,RL1-803 - Published
- 2021
- Full Text
- View/download PDF
3. Multiple cases of sensitization to an antiseptic containing chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol with different profiles of sensitization in adults and children
- Author
-
Charlotte, Beaumont, Anne-Sophie, Darrigade, Annick, Barbaud, Evelyne, Collet, Nadia, Raison-Peyron, Jean-Luc, Bourrain, Haudrey, Assier, Françoise, Giordano-Labadie, Corina, Bara-Passot, Brigitte, Milpied, Florence, Tétart, Pierre, Armingaud, Florence, Castelain, Lamia, Benkalfate, Claire, Boulard, Juliette, Delaunay, Pascale, Mathelier-Fusade, Catherine, Pecquet, Pauline, Pralong, Dominique, Vital-Durand, Nathalie, Genillier Foin, Marine-Alexia, Lefèvre, Florence, Hacard, Audrey, Nosbaum, Justine, Pasteur, Aude, Valois, Martine, Vigan, Marie-Christine, Ferrier le Bouëdec, Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CHU Montpellier, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Toulouse [Toulouse], CHU Bordeaux [Bordeaux], Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de dermatologie, hôpital Jacques-Monod, Le Havre, Département d'allergie et d'immunologie clinique [CHU Lyon Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
recidal-gerda ,Adult ,Chlorhexidine ,contact dermatitis ,Dermatology ,Allergens ,Patch Tests ,allergy ,benzalkonium chloride ,Chlorides ,antiseptic ,Dermatitis, Allergic Contact ,Anti-Infective Agents, Local ,Humans ,Immunology and Allergy ,Benzalkonium Compounds ,Child ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Benzyl Alcohols ,benzyl alcohol ,Retrospective Studies - Abstract
An aqueous antiseptic containing "chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol" (CBB) is widely used in France. The only previous documented study dealing with allergic contact dermatitis (ACD) to this antiseptic is one small case series in children. The French Vigilance Network for Dermatology and Allergy (REVIDAL-GERDA) has collected many cases in the last few years.To evaluate the clinical and sensitization profiles of patients diagnosed with ACD to CBB.We performed a retrospective study of patients with contact dermatitis to CBB and positive tests to CBB and/or at least one of its components. All patients had to be tested with all components of CBB.A total of 102 patients (71 adults and 31 children) were included. The lesions were extensive in 63% of patients and 55% had delayed time to diagnosis. CBB patch tests were positive in 93.8% of cases. The allergen was identified in 97% of patients, mainly benzyl alcohol in adults (81.7%) and chlorhexidine digluconate in children (54.8%). About 32.4% of the patients were sensitized to several components.CBB is a cause of ACD at all ages. The components of the antiseptic should be tested. The sensitization profile seems to be different between adults and children.
- Published
- 2022
- Full Text
- View/download PDF
4. What is the optimal duration for a ROAT? The experience of the French Dermatology and Allergology group (DAG)
- Author
-
Emmanuelle, Amsler, Haudrey, Assier, Angèle, Soria, Corina, Bara, Marie Christine, Ferrier le Bouëdec, Annick, Barbaud, Brigitte, Milpied, Françoise, Giordano-Labadie, Justine, Pasteur, Antoine, Badaoui, Aude, Valois, Florence, Castelain, Flore, Kurihara, Julie, Castagna, Claire, Boulard, Claire, Bernier, Camille, Leleu, Pierre, Marcant, Marie Noelle, Crépy, Florence, Tetart, and Nadia, Raison-Peyron
- Subjects
Dose-Response Relationship, Drug ,Dermatitis, Allergic Contact ,Immunology and Allergy ,Humans ,Dermatology ,Prospective Studies ,Allergens ,Patch Tests - Abstract
The repeated open application test (ROAT) is an adjuvant investigation measure to patch testing in the diagnosis of allergic contact dermatitis. ESCD recommends a 15 days duration but its overall duration varies according to publications and patients hardly adhere to prolonged ROAT duration beyond 1 week.The Dermatology and Allergy Group of the French Society of Dermatology performed a prospective study with the aim of determining the best duration for the ROAT.A total of 328 ROAT results were collected for topical products, including cosmetics (60%) and topical medications (31.1%). Fifty-nine (18%) ROATs were positive, and 16 (5%) were doubtful. All the positive ROATs occurred within 10 days, with a median time to positivity of 3 days.According to our results, a minimum duration of 10 days is necessary to achieve a positive ROAT to a topical product.
- Published
- 2022
5. Nipple Eczema Causing Galactorrhea by Reactive Hyperprolactinemia, Complicated by a Galactocele
- Author
-
Corina Bara-Passot, Elise Cesbron, Hervé Maillard, Arthur Vrignaud, and Kevin Chassain
- Subjects
Galactocele ,Galactorrhea ,medicine.medical_specialty ,business.industry ,Nipple eczema ,medicine ,Case Report ,medicine.symptom ,medicine.disease ,business ,Dermatology - Abstract
We present a case of atopic nipple eczema leading to reactive hyperprolactinemia, by mechanical nipple stimulation. This reactive hyperprolactinemia caused an aggravation of the eczema because of the resulting galactorrhea, by local irritation and inflammation, and was complicated by a galactocele. This benign tumour was a source of concern for the patient and required several diagnostic radiographic examinations.
- Published
- 2021
6. Éruptions eczématiformes chroniques du sujet âgé : quelle imputabilité médicamenteuse ?
- Author
-
Marie Jachiet, Claire Boulard, Delphine Staumont-Sallé, Catherine Droitcourt, Robin Guelimi, Florence Tetart, Julie Bouteiller, Haudrey Assier, Brigitte Milpied, Emilie Brenaut, Julien Grosjean, Manuelle Viguier, Marie-Christine Ferrier Le Bouedec, Pascal Joly, Audrey Nosbaum, Pauline Bouschon, Nadia Raison-Peyron, Corina Bara, A. Valois, J. Delaunay, Justine Pasteur, F. Dezoteux, Saskia Oro, C. Morice, Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CHU de Rouen, Département d’informatique et d’information médicales, Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Département de dermatologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service d'allergologie et immunologie clinique, Centre hospitalier Lyon Sud, Hospices civils de Lyon, Service de Dermatologie, Centre Hospitalier Sud, Hospices Civils, Lyon, Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Dermatology Department [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, Toulon, Service de dermatologie (CHU de Reims), Centre Hospitalier Universitaire de Reims (CHU Reims), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de dermatologie, hôpital Jacques-Monod, Le Havre, Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de Dermatologie et Oncologie Cutanée [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Dermatologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Caen, and Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN)
- Subjects
Médicaments ,Ocean Engineering ,Eczéma ,MESH: Inhibiteurs des canaux calciques ,3. Good health ,MESH: Préparations pharmaceutiques ,030207 dermatology & venereal diseases ,03 medical and health sciences ,MESH: Eczéma ,0302 clinical medicine ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Inhibiteurs calciques ,030220 oncology & carcinogenesis ,Personne âgée ,Safety, Risk, Reliability and Quality ,MESH: Sujet âgé ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
Introduction Le role des medicaments dans la survenue d’eruptions eczematiformes du sujet âge (EESA) a ete suggere dans une etude cas-temoin francaise montrant une frequence de prise des inhibiteurs calciques de 26 % chez les patients ayant une EESA (OR de 2,5 par rapport aux temoins sans eczema). Ces resultats ont ensuite ete confirmes par une etude retrospective americaine. Des cas isoles d’EESA ont depuis ete rapportes avec le clopidogrel, les IEC, les ARAII et les diuretiques. Notre etude initiale ayant ete realisee il y a 15 ans, nous en avons realise une nouvelle pour reevaluer l’association entre les prises medicamenteuses et les EESA. Materiel et methodes Cette etude retrospective a ete conduite dans 16 centres du GREAT, FISARD ou DAG de 2018 a 2020. Nous avons compare la frequence des 10 classes medicamenteuses les plus prescrites entre la population etudiee (patients de plus de 65 ans developpant un eczema chronique sans cause identifiee) et la population generale de reference du meme âge dont les donnees ont ete obtenues grâce a l’Echantillon Generaliste des Beneficiaires (EGB) issu de la base informatique de la Securite Sociale, apres standardisation indirecte sur le sexe et l’âge. Tous les patients inclus avaient des lesions eczematiformes etendues (plus de 20 % de la surface corporelle), depuis plus de 3 mois. Une biopsie cutanee evocatrice d’eczema devait avoir ete realisee ainsi qu’une immunofluorescence directe negative ou des anticorps BPAG 1 et 2 negatifs afin d’eliminer une pemphigoide au stade pre-bulleux. Les patients n’avaient pas d’antecedent de dermatite atopique dans l’enfance. Resultats Cent quatre vingt cinq patients (120 H et 65 F) d’âge moyen 79,5 ± 7,5 ans ont ete inclus. L’hypertension arterielle representait la comorbidite la plus frequente (69,7 % des patients). Les patients prenaient en moyenne 5,0 ± 3,2 medicaments. Les medicaments les plus frequemment prescrits etaient les inhibiteurs calciques (39,5 %), les statines (36,8 %), les antiagregants plaquettaires (31,9 %), les betabloquants (30,8 %), les ARA2 (29,2 %), les diuretiques thiazidiques (23,8 %), les IEC (22,7 %), les IPP (21,6 %), les diuretiques de l’anse (17,8 %) et les benzodiazepines (15,1 %). Un ou plusieurs medicaments etaient arretes chez 60 (32,4 %) patients. Parmi eux, 31 (51,7 %) ne presentaient plus de lesion a 6 mois. L’analyse comparative par rapport a l’EGB est en cours. Discussion Les caracteristiques des patients concordent avec celles observees dans notre etude precedente, en particulier la predominance masculine et la polymedication. La frequence de prise des inhibiteurs calciques (39,5 %) est encore plus elevee (× 1,5) que dans notre etude initiale confirmant le tres fort risque lie a cette classe medicamenteuse. La comparaison avec les donnees de l’EGB (analyse en cours avec resultats prevus prochainement) permettra peut-etre de mettre en evidence une association avec d’autres classes medicamenteuses.
- Published
- 2021
- Full Text
- View/download PDF
7. Durée optimale du ROAT, expérience du groupe dermato allergologie de la Société française de dermatologie
- Author
-
Corina Bara, A. Valois, Marie Christine Ferrier Le Bouedec, Justine Pasteur, A. Hamelin, Françoise Giordano-Labadie, Claire Boulard, Camille Leleu, P. Marcant, Nadia Raison-Peyron, A. Barbaud, Claire Bernier, Marie Noelle Crepy, Brigitte Milpied, Florence Tetart, Julie Castagna, Antoine Badaoui, Florence Castelain, Haudrey Assier, Emmanuelle Amsler, Angèle Soria, and Flore Kurihara
- Subjects
Ocean Engineering ,Safety, Risk, Reliability and Quality - Published
- 2021
- Full Text
- View/download PDF
8. Bilan allergologique des érythèmes pigmentés fixes : une étude multicentrique FISARD
- Author
-
A. Valois, Tullia De Risi, A. Barbaud, G. Gener, Juliette Delauney, Flore Kurihara, Claire Bernier, Angèle Soria, Hélène Traineau, Marie Christine Ferrier Le Bouedec, Corina Bara, Fabien Pelletier, Florence Castelain, O. Bauvin, Emmanuelle Amsler, Florence Tetart, A. Hamelin, Brigitte Milpied, and Haudrey Assier
- Subjects
Ocean Engineering ,Safety, Risk, Reliability and Quality - Published
- 2021
- Full Text
- View/download PDF
9. Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases
- Author
-
Vincent Descamps, Angèle Soria, B. Bensaid, Catherine Prost-Squarcioni, Corina Bara Passot, Marie Beylot-Barry, Sabine Grootenboer-Mignot, Bethsabée Garel, Bénédicte Lebrun-Vignes, Sophie Duvert-Lehembre, Florence Tetart, Saskia Ingen-Housz-Oro, Daniele Afriat, Géraldine Jeudy, Annick Barbaud, Frédéric Caux, and Marie Blanche Valnet-Rabier
- Subjects
Male ,Databases, Factual ,Minocycline ,030226 pharmacology & pharmacy ,Severity of Illness Index ,Pharmacovigilance ,0302 clinical medicine ,Prevalence ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Child ,media_common ,Aged, 80 and over ,Mucous membrane ,Middle Aged ,Linear IgA Bullous Dermatosis ,medicine.anatomical_structure ,Child, Preschool ,Doxycycline ,Vancomycin ,Female ,France ,Drug Monitoring ,medicine.drug ,Drug ,Adult ,medicine.medical_specialty ,Linear IgA bullous dermatosis ,Adolescent ,media_common.quotation_subject ,Diagnosis, Differential ,03 medical and health sciences ,Young Adult ,Humans ,Enoxaparin ,Direct fluorescent antibody ,Aged ,Retrospective Studies ,Pharmacology ,business.industry ,Original Articles ,medicine.disease ,Dermatology ,Toxic epidermal necrolysis ,Stevens-Johnson Syndrome ,business - Abstract
Aims Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. Methods Data for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method. Results Of the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges. Conclusions There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.
- Published
- 2018
10. The European Standard Series and its additions: are they of any use in 2013?
- Author
-
Marie Christine Ferrie Le Bouedec, Michel Castelain, Dominique Tennstedt, Isabelle Lartigaud, Florence Castelain, Annick Barbaud, Nadia Raison-Peyron, M. Vigan, Florence Tetard, Julie Waton, P. Girardin, Gilbert Jelen, Haudrey Assier, Marie Baeck, Corina Bara, Christian Frick, Brigitte Felix, and Marie Claude Jacobs
- Subjects
medicine.medical_specialty ,Series (stratigraphy) ,European community ,business.industry ,Dermatology ,Allergens ,Reference Standards ,Dermatitis, Contact ,medicine.disease ,Surgery ,Europe ,Family medicine ,Humans ,Medicine ,European standard ,Contact allergens ,Allergists ,business ,Contact dermatitis ,Skin Tests - Abstract
This study has two purposes:--to know whether the European standard series is still the key reference when it comes to contact dermatitis, i.e., are its components still the most frequently involved allergens in contact dermatitis nowadays?--to assess the results of the European standard series among French and Belgian dermatologists/allergists as, so far, most of them have failed to provide statistical data within the European community of allergists/dermatologists. 18 participants from 2 dermatology and allergy centres in Belgium and 11 centres in France collected their results from 3,073 patients tested in 2011. They assessed the relevance of some tests as well as that of the standard series and additional series to establish an etiological diagnosis of contact dermatitis. These results, together with the history of the European standard series, have shown that some allergens are obsolete and that others should be included in a new standard series for which we are making a few suggestions.
- Published
- 2014
- Full Text
- View/download PDF
11. Methotrexate for Bullous Pemphigoid: Preliminary Study
- Author
-
Corina Bara, Nicole Briand, Phillipe Celerier, and Hervé Maillard
- Subjects
medicine.medical_specialty ,Pemphigoid ,business.industry ,MEDLINE ,Dermatology ,General Medicine ,medicine.disease ,Clinical trial ,Dermatologic agents ,medicine ,Methotrexate ,Bullous pemphigoid ,business ,medicine.drug - Published
- 2003
- Full Text
- View/download PDF
12. Tumeur unguéale rare : l’onychomatricome. À propos d’un cas
- Author
-
Yvon Moui, Laurent Pidhorz, Prune Alligand-Perrin, Michael Benassayag, Anne-Laure Champdavoine, and Corina Bara-Passot
- Subjects
Orthopedics and Sports Medicine ,Surgery ,General Medicine - Abstract
Lesion fibro-epitheliale rare de la matrice ungueale (quelques dizaines de cas decrits), l’onychomatricome est une tumeur benigne, dont le traitement est l’exerese chirurgicale. Decrite en 1992 par Baran et Kint, elle presente des caracteristiques cliniques et histopathologiques tres particulieres qui permettent le plus souvent d’en faire le diagnostic. Doivent etre evoques les diagnostics de fibrokeratome, fibrome ungueal et maladie de Bowen en cas d’hyperpigmentation. Il n’y a pas d’examens complementaires a pratiquer devant un aspect clinique typique. L’aspect de la tablette ungueale apres exerese permet de retenir le diagnostic. Observation clinique Une femme de 46 ans se presentait a la consultation pour un ongle dystrophique isole de l’index droit, evoluant depuis 2 ans au moins, avec comme seule plainte un ongle disgracieux. Elle ne presentait aucune douleur, pas de deficit sensitif, pas d’inflammation locale. La dystrophie n’etait presente que sur la partie mediale de l’ongle, respectant la zone laterale saine. Une tumefaction nodulaire etait visible a la base de l’ongle sur la zone matricielle. La radiographie etait normale. L’epaississement longitudinal jaunâtre evoquant initialement une onychomycose, des prelevements mycotiques ont ete realises au laboratoire, revenant negatifs. Apres un avis aupres de nos confreres dermatologues, l’onychomatricome a ete evoque devant des caracteristiques cliniques typiques : epaississement de l’ongle sur toute sa longueur mais variable en largeur (respectant une partie d’ongle sain), une hypercourbure longitudinale et transversale de la tablette, une xanthonychie longitudinale, hemoragies filiformes proximales et distales, une tumefaction nodulaire de la base. Une exerese chirurgicale a ete realisee. Ablation de la tablette ungueale, apres avoir recline l’eponychium. On visualisait alors la tumeur matricielle qui etait dissequee puis resequee. Apres fermeture de l’eponychium, le lit n’a pas ete recouvert. Macroscopiquement la tablette etait epaissie et perforee de cavites cylindriques, et la tumeur matricielle presentait des digitations, type « tentacules », extraites de la tablette lors de son exerese. A 6 mois, la repousse ungueale est bonne et sans recidive.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.